DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCompany

Alembic Pharmaceuticals Limited — Investor Presentation

NSE 3 hrs ago·4 Aug 2026, 8:44 am

Company NSE

Alembic Pharmaceuticals Limited has submitted its investor presentation to the stock exchange. This document typically outlines the company's future growth strategies, financial performance, and operational roadmap for the upcoming quarters.

For investors, this update is a key opportunity to understand management's vision and assess the company's direction. It provides clarity on how Alembic plans to navigate the competitive landscape and achieve its targets.

Investors should focus on the guidance provided regarding revenue growth, margin expansion, and new product launches. Keeping an eye on the management's commentary during any subsequent earnings calls will be crucial for gauging the company's execution capabilities.